In yesterday’s Wall Street session, LivaNova PLC (NASDAQ:LIVN) shares traded at $44.34, down -2.33% from the previous session.
7 analysts cover LivaNova PLC (NASDAQ:LIVN), according to research data. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $80.00 and a low of $60.00, we find $67.50. Given the previous closing price of $45.40, this indicates a potential upside of 48.68 percent. LIVN stock price is now -18.24% away from the 50-day moving average and -21.45% away from the 200-day moving average. The market capitalization of the company currently stands at $2.39B.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
The stock has received a hold rating from 1 analysts and a buy rating from 5. Brokers who have rated the stock have averaged $69.00 as their price target over the next twelve months.
With the price target of $62, Barclays recently initiated with Equal Weight rating for LivaNova PLC (NASDAQ: LIVN). On April 06, 2022, Wolfe Research recently initiated its ‘Outperform’ rating on the stock quoting a target price of $95, while ‘UBS’ rates the stock as ‘Buy’.
In other news, McDonald Damien, CEO sold 2,220 shares of the company’s stock on Dec 15. The stock was sold for $121,123 at an average price of $54.56. Upon completion of the transaction, the CEO now directly owns 83,749 shares in the company, valued at $3.71 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 01, Director Moore Daniel Jeffrey sold 1,000 shares of the business’s stock. A total of $83,416 was realized by selling the stock at an average price of $83.42. This leaves the insider owning 24,630 shares of the company worth $1.09 million. Insiders disposed of 23,439 shares of company stock worth roughly $1.04 million over the past 1 year. A total of 0.39% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in LIVN stock. A new stake in LivaNova PLC shares was purchased by JEFFERIES FINANCIAL GROUP INC. during the first quarter worth $13,471,000. P SCHOENFELD ASSET MANAGEMENT LP invested $6,016,000 in shares of LIVN during the first quarter. In the first quarter, CORONATION FUND MANAGERS LTD. acquired a new stake in LivaNova PLC valued at approximately $5,126,000. ADAGE CAPITAL PARTNERS GP, L.L.C. acquired a new stake in LIVN for approximately $4,434,000. AMALGAMATED FINANCIAL CORP. purchased a new stake in LIVN valued at around $1,586,000 in the second quarter.
On Tuesday morning LivaNova PLC (NASDAQ: LIVN) stock kicked off with the opening price of $45.44. During the past 12 months, LivaNova PLC has had a low of $41.82 and a high of $88.00. As of last week, the company has a debt-to-equity ratio of 0.45, a current ratio of 3.00, and a quick ratio of 2.50. The fifty day moving average price for LIVN is $54.23 and a two-hundred day moving average price translates $56.45 for the stock.
The latest earnings results from LivaNova PLC (NASDAQ: LIVN) was released for Sep, 2022. According to the Medical Devices Company, earnings per share came in at $0.58, beating analysts’ expectations of $0.54 by 0.04. This compares to -$0.05 EPS in the same period last year. The net profit margin was -8.40% and return on equity was -7.00% for LIVN. The company reported revenue of $274.87 million for the quarter, compared to $270.06 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 1.78 percent. For the current quarter, analysts expect LIVN to generate $262.58M in revenue.
LivaNova PLC(LIVN) Company Profile
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
